Acceleron receives FDA breakthrough therapy designation for sotatercept in pulmonary arterial hypertension
“In January of this year, we reported positive topline results from our PULSAR Phase 2 placebo-controlled trial of sotatercept in patients with PAH,” said Habib Dable, President and